Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...

Meniscus Tear Clinical Trial Progression: The market is poised for substantial growth, fueled by the anticipated launch of ...

Moderna stock was slumping Thursday after it announced a major pullback in its research and development efforts, as the ...

Ethereum, or 1 ETH, traded at $2,636.77 as of 8 a.m. ET. The highest intraday price the cryptocurrency reached in the past ...

Maky Zanganeh, Co-CEO of Summit Therapeutics' owns 5% of the biopharmaceutical company and stock options. One of the 34 ...

Ethereum, or 1 ETH, traded at $2,644.63 as of 8 a.m. ET. The highest intraday price the cryptocurrency reached in the past ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.